Legend Biotech (LEGN) Net Income towards Common Stockholders (2019 - 2025)

Legend Biotech has reported Net Income towards Common Stockholders for 7 years, with the latest figure at $2.5 million in Q4 2025.

• For the quarter ending Q4 2025, Net Income towards Common Stockholders rose 104.24% year-over-year to $2.5 million; the trailing twelve-month figure through Dec 2025 stood at -$261.1 million (up 41.1% YoY), and the FY2025 full-year result was $33.1 million, up 117.53% from the prior year.
• Net Income towards Common Stockholders for Q4 2025 stood at $2.5 million, up from -$38.5 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $2.5 million in Q4 2025, with the low at -$199.1 million in Q2 2023.
• Historically, Net Income towards Common Stockholders has averaged -$95.9 million across 5 years, with a median of -$90.1 million in 2021.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders slumped 35570.18% — and 2025, when it jumped 104.24%.
• Legend Biotech's Net Income towards Common Stockholders stood at -$88.3 million in 2021, then sank by 53.82% to -$135.9 million in 2022, then jumped by 34.83% to -$88.5 million in 2023, then jumped by 33.37% to -$59.0 million in 2024, then surged by 104.24% to $2.5 million in 2025.
• The last three Net Income towards Common Stockholders figures came in at $2.5 million (Q4 2025), -$38.5 million (Q3 2025), and -$124.2 million (Q2 2025), per Business Quant data.